Publications

5813 Results

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201

Authors
B Andreadis;N Bartlett;J Leonard;P Stiff;J Friedberg;TBA
Journal / Conference
Leuk Lymphoma. 2025 Oct;66(10):1903-1912. doi: 10.1080/10428194.2025.2525982. Epub 2025 Jul 9.NIHMS2093959
Year
2025
Research Committee(s)
Lymphoma
PMID
PMID40632607
PMC
PMC12321088
Study Number(s)
CTSU/A051301

Advanced Stage classical Hodgkin Lymphoma Patients with a Positive Interim-PET (PET-2) Deauville Score 5 After 2 ABVD Cycles: A Pooled Analysis of Three Multicenter Trials

Authors
S Viviani;S Pavoni;S Barrington;L Guerra;H Schoder;P Johnson;A Kirkwood;D Stephens;J Friedberg;S Chauvie;M Knopp;S Luminari;D Molin;P Corradini;A Gallamini;A Rambaldi;C Tarella
Journal / Conference
Blood Cancer Journal. 2025 Oct 16;15(1):165. doi: 10.1038/s41408-025-01364-z.
Year
2025
Research Committee(s)
Lymphoma
PMID
41102172
PMC
PMC12533113
Study Number(s)
S0816

Optimizing Palliative Cancer Surgery Trial Completion: Lessons Learned From Qualitative Content Analysis of S1316 - Comparative Effectiveness Trial for Malignant Bowel Obstruction

Authors
M Farooq;N Amini;V Sun;G Deutsch;J Deneve;M Grant;K Arnold;A Secord;G Anderson;R Krouse
Journal / Conference
Am J Hosp Palliat Care. 2025 Oct 29:10499091251391420. doi: 10.1177/10499091251391420. Online ahead of print.
Year
2025
Research Committee(s)
Palliative Care
PMID
41159270
Study Number(s)
S1316

The Influence of Age on Patient-Reported Outcomes (PROs) Endpoints on the S1826 Cross-Network Phase III trial of Advanced-Stage, Classic Hodgkin Lymphoma (cHL) (3891/4500)

Authors
K Davison;J Unger;H Li;S Castellino;H Dillon;T Hernandez;S Rutherford;A Punnett;M LeBlanc;J Song;S Smith;A Evens;K Kelly;J Friedberg;A Herrera;S Parsons
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL). poster abstract 2738. Blood (2025) 146 (Supplement 1): 2738
Year
2025
Research Committee(s)
Lymphoma
Study Number(s)
S1826

Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan in Older Adults with Acute Myeloid Leukemia (AML) Receiving Intensive Induction Chemotherapy (Alliance A041701)

Authors
G Uy;J Yin;S Dinner;D DeAngelo;J Liesveld;J Kolitz;A Asch;O Odenike;O Kour;R Teske;K Skogen;K Byrd;R Little;A Carroll;K Mrozek;A Eisfeld;J Byrd;A Jaslowski;H Erba;M Litzow;W Stock;R Stone
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL). poster. Blood (2025) 146 (Supplement 1): 3415. doi: 10.1182/blood-2025-3415
Year
2025
Research Committee(s)
Leukemia

Biallelic TP53 aberrations and double TP53 mutations are prevalent in AML/MDS patients with del(5q) complex karyotype - An NCI myeloMATCH and SWOG Report

Authors
M Fang;K Kroeger;T Nguyen;X Qu;C Yeung;S Jiwani;B Wood;L Harris;H Erba;M Othus;J Radich;R Little
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL). Abstract 5276 poster. Blood (2025) 146 (Supplement 1): 5276
Year
2025
Research Committee(s)
Leukemia
Study Number(s)
MM1YA-S01

Improving Karyotype Success for myeloMATCH: Evidence-Based Culturing Optimization for Rapid AML Screening - An NCI myeloMATCH and SWOG Report

Authors
X Qu;S Mcclung;N Shepherd;K Kroeger;B Hale;M Othus;H Erba;L Harris;R Little;J Radich;M Fang
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL). Abstract 3473 poster. Blood (2025) 146 (Supplement 1): 3473
Year
2025
Research Committee(s)
Leukemia
Study Number(s)
MM1YA-S01

RADIOTHERAPY PATTERNS OF CARE IN PATIENTS WITH NODAL MICROMETASTASES: A SECONDARY SUBGROUP ANALYSIS OF SWOG 1007

Authors
J Bazan;A Meisner;K Kalinsky;E Connolly;W Barlow;W Woodward;A Thompson;P Sharma;L Pusztai;R Jagsi
Journal / Conference
San Antonio Breast Cancer Symposium (December 9-12, 2025, San Antonio, TX)
Year
2025
Research Committee(s)
Breast
Study Number(s)
S1007

3-Year Follow-up of the S1826 Study Confirms Improved Progression-Free Survival with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma

Authors
A Herrera;M LeBlanc;S Castellino;H Li;S Rutherford;A Evens;K Davison;A Punnett;S Parsons;S Ahmed;C Casulo;N Bartlett;J Tuscano;M Mei;B Hess;R Jacobs;B Hu;C Moskowitz;C Forlenza;A Doan;A Lamble;D Hodgson;M Knopp;P Hernandez;R Little;M Shipp;RM Crump;B Kahl;JP Leonard;S Smith;J Song;K Kelly;J Friedberg
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL). #151 oral. Blood (2025) 146 (Supplement 1): 151.
Year
2025
Research Committee(s)
Lymphoma
Study Number(s)
S1826

MyeloMATCH: Successful screening and clinical-pathologic features of the first 550 patients

Authors
E Winer;M Othus;E Atallah;S Tsai;M Sabloff;A Osman;A Im;S Loghavi;A Moseley;J Shahanawaz;B Wood;M Fang;C Yeung;X Chen;X Qu;S Ghatak;S Gore;G Uy;L Michaelis;T Odenike;R Stone;S Lugar;S Assouline;H Erba;M Litzgow;C Lachowiez;J Reagan;U Borate;L Savoie;B Jonas;N Roy;J Radich;R Little
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL). #5279 poster. Blood (2025) 146 (Supplement 1): 5279.
Year
2025
Research Committee(s)
Leukemia
Study Number(s)
MYELOMATCH